Promotions, promotions, promotions,...
They missed one (see attachment at end). <g>
Miljenko
Monday February 12, 10:52 am Eastern Time
Press Release
Regeneron Announces Executive Appointments
Yancopoulos Named President, Regeneron Research Laboratories, Chief Scientific Officer, and Executive Vice President
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Feb. 12, 2001--Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - news) today announced that George D. Yancopoulos, M.D., Ph.D., has been named President, Regeneron Research Laboratories, Chief Scientific Officer, and Executive Vice President. Previously he was Senior Vice President, Research and Chief Scientific Officer.
Dr. Yancopoulos joined Regeneron in 1989.
Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron, commented, ``We believe that George Yancopoulos is one of the premier scientists of his generation. The major contributions he has made since the opening of Regeneron's laboratories have enabled Regeneron to be in the position of developing a diverse pipeline of potential drugs to address major unmet medical needs. Moreover, the technology platforms he has developed at Regeneron are critical to our efforts to capitalize on the genomics revolution.''
The Company also announced appointment of the following senior vice presidents:
Murray A. Goldberg has been named Senior Vice President, Finance & Administration, Chief Financial Officer, Treasurer, and Assistant Secretary. Previously he was Vice President, Finance & Administration, Chief Financial Officer, Treasurer, and Assistant Secretary. Mr. Goldberg joined Regeneron in 1995.
Randall G. Rupp, Ph.D., has been named Senior Vice President, Manufacturing and Process Sciences. Previously he was Vice President, Manufacturing and Process Sciences. Dr. Rupp joined Regeneron in 1992.
Neil Stahl, Ph.D., has been named Senior Vice President, Preclinical Development and Biomolecular Science. Previously he was Vice President, Preclinical Development and Biomolecular Science. Dr. Stahl joined Regeneron in 1991. Dr. Schleifer added, ``The challenge of developing new drugs to address important medical conditions requires a dedicated and talented senior management team. These promotions reflect the contributions that these individuals have made to the success of Regeneron. They each have proven track records and will continue to lead their respective areas. In addition, to support the continued growth of the Company and our expanding preclinical and clinical pipeline, we have also named a number of other Regeneron veterans to management positions.''
The Company announced appointment of the following vice presidents:
-- Ann L. Acheson, Ph.D. - Vice President, Product Development
Operations & Logistics. Previously she was Team Leader,
AXOKINE®. Dr. Acheson joined Regeneron in 1992.
-- Kevin M. Bailey, Ph.D. - Vice President, Preclinical Manufacturing
& Process Development. Previously he was Senior Director, Research
Manufacturing & Process Development. Dr. Bailey joined Regeneron
in 1991.
-- Thomas J. Daly, Ph.D. - Vice President, Protein Chemistry
Sciences. Previously he was Senior Director, Protein Sciences. Dr.
Daly joined Regeneron in 1995.
-- James P. Fandl, Ph.D. - Vice President, Protein Expression
Sciences. Previously he was Senior Director, Protein Sciences. Dr.
Fandl joined Regeneron in 1989.
-- David J. Glass, M.D. - Vice President, Muscle Program & Technology
Development. Previously he was Director, Muscle Program. Dr. Glass
joined Regeneron in 1991.
-- Andrew Murphy, Ph.D. - Vice President, Gene Discovery &
Bioinformatics. Previously he was Director, Genomics &
Bioinformatics. Dr. Murphy joined Regeneron in 1999.
-- Stanley J. Wiegand, Ph.D. - Vice President, Neural, Endocrine &
Obesity Research. Previously he was Senior Director, Neural &
Endocrine Biology. Dr. Wiegand joined Regeneron in 1990.
--------------------------------------------------------------------------------
MZ was promoted to first class Company *hyper*.
He joined REGN,... somewhere in pass. |
